Can response duration after the first rituximab treatment be used in timing of rituximab retreatment?

N van HerwaardenDepartment of Rheumatology, St. Maartens Clinic, Nijmegen, The NetherlandsCorrespondence[email protected]

A van der MaasDepartment of Rheumatology, St. Maartens Clinic, Nijmegen, The Netherlands

TL JansenDepartment of Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

EAJ DutmerDepartment of Rheumatology, Gelderse Vallei Hospital, Ede, The Netherlands

A HartkampDepartment of Rheumatology, Jeroen Bosch Hospital, Den Bosch, The Netherlands

PLCM van RielDepartment of Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

W KievitDepartment of Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

BJF van den BemtDepartment of Pharmacy, St. Maartens Clinic, Nijmegen, The Netherlands

AA den BroederDepartment of Rheumatology, St. Maartens Clinic, Nijmegen, The Netherlands

show all

References

Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, . Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909–20.
PubMed Web of Science ®Google Scholar
Blom M, Kievit W, Donders ART, den Broeder AA, Straten VHHP, Kuper I, . Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. J Rheumatol 2011;38:2355–61.
PubMedGoogle Scholar
Welsing PMJ, Landewé RBM, van Riel PLCM, Boers M, van Gestel AM van der Linden S, . The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082–93.
PubMed Web of Science ®Google Scholar
Teng YKO, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JWJ, van Laar JM. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell treatment strategies. Ann Rheum Dis 2009;68:1075–7.
PubMedGoogle Scholar
Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Müller-Ladner U, Gaylis NB, . Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology 2011;50:2223–32.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Can response duration after the first rituximab treatment be used in timing of rituximab retreatment?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Can response duration after the first rituximab treatment be used in timing of rituximab retreatment?

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date